These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 22888144)

  • 1. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
    Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
    J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
    Modjtahedi H; Cho BC; Michel MC; Solca F
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Jun; 387(6):505-21. PubMed ID: 24643470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
    Khelwatty SA; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2011 Aug; 39(2):483-91. PubMed ID: 21617858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
    Kwak EL; Shapiro GI; Cohen SM; Becerra CR; Lenz HJ; Cheng WF; Su WC; Robohn M; Le Maulf F; Lobmeyer MT; Chand VK; Iafrate AJ
    Cancer; 2013 Aug; 119(16):3043-51. PubMed ID: 23775486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
    Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
    Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
    De Grève J; Teugels E; Geers C; Decoster L; Galdermans D; De Mey J; Everaert H; Umelo I; In't Veld P; Schallier D
    Lung Cancer; 2012 Apr; 76(1):123-7. PubMed ID: 22325357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
    Sos ML; Rode HB; Heynck S; Peifer M; Fischer F; Klüter S; Pawar VG; Reuter C; Heuckmann JM; Weiss J; Ruddigkeit L; Rabiller M; Koker M; Simard JR; Getlik M; Yuza Y; Chen TH; Greulich H; Thomas RK; Rauh D
    Cancer Res; 2010 Feb; 70(3):868-74. PubMed ID: 20103621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
    Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
    Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
    Zhang S; Zheng X; Huang H; Wu K; Wang B; Chen X; Ma S
    Oncotarget; 2015 Mar; 6(8):5832-45. PubMed ID: 25714021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
    Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
    J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
    Carmi C; Cavazzoni A; Vezzosi S; Bordi F; Vacondio F; Silva C; Rivara S; Lodola A; Alfieri RR; La Monica S; Galetti M; Ardizzoni A; Petronini PG; Mor M
    J Med Chem; 2010 Mar; 53(5):2038-50. PubMed ID: 20151670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
    Mao X; Chen Z; Zhao Y; Yu Y; Guan S; Woodfield SE; Vasudevan SA; Tao L; Pang JC; Lu J; Zhang H; Zhang F; Yang J
    Oncotarget; 2017 Jan; 8(1):1555-1568. PubMed ID: 27902463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
    Schaefer G; Shao L; Totpal K; Akita RW
    Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
    Kobayashi S; Ji H; Yuza Y; Meyerson M; Wong KK; Tenen DG; Halmos B
    Cancer Res; 2005 Aug; 65(16):7096-101. PubMed ID: 16103058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical perspective of afatinib in non-small cell lung cancer.
    Chen X; Zhu Q; Zhu L; Pei D; Liu Y; Yin Y; Schuler M; Shu Y
    Lung Cancer; 2013 Aug; 81(2):155-61. PubMed ID: 23664448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
    Peters S; Zimmermann S; Adjei AA
    Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diarrhea associated with afatinib: an oral ErbB family blocker.
    Yang JC; Reguart N; Barinoff J; Köhler J; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Wolf J; Cohen EE
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):729-36. PubMed ID: 23506556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.